Boehringer/Lilly's Jardiance Wows With CVOT Data
This article was originally published in Scrip
"Wonderful" and "profound" were just two of the adjectives thrown around at Sept. 17's symposium presentation of Boehringer Ingelheim and Eli Lilly & Co.'s EMPA-REG OUTCOMES study, the cardiovascular outcomes trial for their type 2 diabetes therapy Jardiance (empagliflozin), at the European Association for the Study of Diabetes.
You may also be interested in...
Heart Failure Pipeline Review: Amgen's Omecamtiv And Merck's Vericiguat Step Up To Plate
In addition to small molecules, stem cell therapies promise to help rejuvenate the chronic heart failure pipeline, but high prices and invasive procedures may limit their use to end-stage patients, and skepticism about efficacy persists.
Jardiance's Label Expansion Will Change Diabetes Management
US approval of the first cardiovascular label expansion for an anti-diabetic medicine will mark a shift in disease management, says Datamonitor Healthcare analyst Kevin Shannon.
BI/Lilly's Jardiance Is First Diabetes Drug With CV Benefit Claim
Companies are supporting new US-labeled indication for cardiovascular mortality risk reduction with a consumer education campaign, direct-to-consumer advertising and cardiologist detailing.